祥生医疗 (688358.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	435.4M	435.8M	468.7M	483.8M	380.8M
Cost of Revenue	178.5M	178.3M	192.4M	202.8M	155.1M
Gross Profit	256.9M	257.6M	276.3M	281.0M	225.8M
Operating Expenses
R&D Expense	77.3M	74.5M	79.6M	77.1M	77.9M
SG&A Expense	—	—	—	—	—
General & Admin Expense	37.2M	36.6M	37.6M	34.9M	33.3M
Selling & Marketing Expense	52.5M	54.5M	55.0M	49.3M	50.3M
Other Expenses	—	—	—	—	—
Total Operating Expenses	147.2M	143.2M	135.4M	141.6M	136.4M
Cost and Expenses	325.7M	321.4M	327.8M	344.4M	291.5M
Operating Income (EBIT)	128.1M	126.9M	157.3M	162.2M	115.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	131.7M	128.6M	156.8M	162.2M	115.1M
Income Tax Expense	10.8M	12.1M	16.3M	15.7M	9.3M
Bottom Line
Net Income	120.9M	116.5M	140.5M	146.5M	105.8M
Earnings from Cont. Ops	120.9M	116.5M	140.5M	146.5M	105.8M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	120.9M	116.5M	140.5M	146.5M	105.8M
Per Share
Basic EPS	CN¥1.08	CN¥1.04	CN¥1.26	CN¥1.33	CN¥0.94
Diluted EPS	CN¥1.08	CN¥1.04	CN¥1.26	CN¥1.33	CN¥0.94
Revenue Per Share	CN¥3.88	CN¥3.89	CN¥4.20	CN¥4.39	CN¥3.38
Shares
Basic Shares Outstanding	112.3M	112.0M	111.5M	110.1M	112.6M
Diluted Shares Outstanding	112.3M	112.0M	111.5M	110.1M	112.6M
Profitability Metrics
EBITDA	—	138.4M	169.3M	173.9M	127.3M
D&A	—	11.4M	12.0M	11.7M	12.2M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026